As a fast-growing company, BioLizard has been recognised as one of the companies to watch in 2025!
This recognition is part of a joint initiative by Trends, Change the Game, and Kanaal Z, which closely monitors companies achieving the greatest growth based on value creation, expanding and knowledgeable workforces.
We are thrilled about this nomination and proud to be seen as a source of energy and inspiration for entrepreneurs.
Well done BioLizard team
For over a century, the life sciences industry has relied on animal models as the standard for predicting drug safety and effect. But today, the industry faces a harsh reality: over 90% of new drugs that appear safe and effective in animal tests ultimately fail in human clinical trials (see for example Ineichen et al. 2024 [1] and Marshall et al. 2023[2])
Oncology drug development often begins in patients, allowing early safety and efficacy insights. Yet many cancer drugs still fail in the clinic. We validate the target but ignore its context within the tumor microenvironment. This article explores why spatial biology may improve clinical success.
BioLizard has been named “Bioinformatics Innovation of the Year” in the 2025 BioTech Breakthrough Awards. The honor spotlights Bio|Verse® Navigator, a visual analytics workspace that unifies complex R&D data so scientists can decide faster, with confidence.
